anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
NeuroSense Therapeutics · pitchdeck

NeuroSense Therapeutics | Investor Presentation Deck | 33 slides

33 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

NeuroSense Therapeutics | Investor Presentation Deck | 33 slides

NeuroSense Therapeutics · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 17 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Agitate 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits
— 0/3 slides
33.3% 1/3 slides
— 0/3 slides
100% 3/3 slides 100% 3/3 slides Solution 12 slides 100% 12/12 slides 100% 12/12 slides · 61 hits
— 0/12 slides
66.7% 8/12 slides
— 0/12 slides
100% 12/12 slides
— 0/12 slides
Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

33
every slide · same image gating as the playbook
01
Slide 1
Features a 3D rendering of a synapse.front_matter
Open slide detail
02
other
Open slide detail
03
summarize
Open slide detail
04
The slide uses a standard pharmaceutical pipeline visualization (Discovery to NDA).plan_implementation
Open slide detail
05
Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.frame_problem
Open slide detailBeat · Problem
06
The slide uses a biological mechanism-of-action illustration to show how the drug components interact with specific cellular stressors.present_solution
Open slide detailBeat · Solution
07
The slide uses a combination of a biological mechanism diagram and a pharmacokinetic line chart to prove efficacy.present_solution
Open slide detailBeat · Solution
08
Includes a process diagram for iPSC generation and two charts: a survival curve and a hazard ratio bar chart.show_traction
Open slide detailBeat · Solution
09
The chart demonstrates that PrimeC aligns the peak concentrations of two different drugs, which is the core value proposition of their formulation technology.present_solution
Open slide detailBeat · Solution
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.show_traction
Open slide detailBeat · Solution
11
Includes details on screen failures and co-treatment with Riluzole.plan_implementation
Open slide detailBeat · Solution
12
Uses numbered icons for primary/secondary and a lightbulb icon for exploratory.present_framework
Open slide detailBeat · Solution
13
Includes a footnote citation for the methodology definitions.analyze_data
Open slide detailBeat · Solution
14
other
Open slide detailBeat · Solution
15
The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.analyze_data
Open slide detailBeat · Solution
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).show_traction
Open slide detailBeat · Solution
17
The slide highlights a statistically significant 37.4% reduction in disease progression for the Per Protocol population, while noting a 29% reduction (p=0.12) fshow_traction
Open slide detailBeat · Solution
18
The slide uses icons to represent functional domains and provides specific clinical examples of what a 1-point change means for patient quality of life.establish_context
Open slide detailBeat · AgitateLoop · Cost Of Inaction
19
The chart visualizes the reduction in point loss, highlighting the efficacy of PrimeC.show_traction
Open slide detailBeat · AgitateLoop · Cost Of Inaction
20
The slide uses a human silhouette to categorize ALS symptoms into four domains, then presents bar charts for each domain comparing treatment vs placebo.show_traction
Open slide detailBeat · AgitateLoop · Cost Of Inaction
21
The chart highlights a 17.2% attenuation in the decline of SVC scores for the PrimeC group compared to placebo.show_traction
Open slide detail
22
The slide uses a series of blue blocks to represent different research pillars/methodologies within the PARADIGM trial.present_solution
Open slide detail
23
The slide uses a case study to validate the business model of combination therapies.cite_precedent
Open slide detail
24
summarize
Open slide detailBeat · Market Size
25
The slide presents clinical biomarker data comparing control vs AD groups across 6 different markers, using Mann-Whitney U tests for significance.show_traction
Open slide detail
26
The slide outlines the RoAD study parameters including patient population, dosing, and primary/secondary endpoints.present_framework
Open slide detail
27
The slide uses a grid layout to display five key advisors with their respective credentials and logos of their affiliated institutions.other
Open slide detail
28
The slide uses a grid layout to present institutional and corporate partners.other
Open slide detail
29
plan_implementation
Open slide detail
30
Slide 30 of the deck.state_next_steps
Open slide detailLoop · Quick Win Big Bet
31
The chart shows a clear divergence between the treatment and placebo arms over time, with a 29.2% difference at the 180-day mark.show_traction
Open slide detail
32
The chart shows a divergence in SVC decline between the treatment and placebo groups over time.show_traction
Open slide detail
33
Data includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various motor and respiratory domains.analyze_data
Open slide detail